Tormo E - Search Results

1

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer.

Adam-Artigues A, Arenas EJ, Martínez-Sabadell A, Brasó-Maristany F, Cervera R, Tormo E, Hernando C, Martínez MT, Carbonell-Asins J, Simón S, Poveda J, Moragón S, Zazo S, Martínez D, Rovira A, Burgués O, Rojo F, Albanell J, Bermejo B, Lluch A, Prat A, Arribas J, Eroles P, Cejalvo JM. Adam-Artigues A, et al. Among authors: tormo e. Sci Adv. 2022 May 20;8(20):eabk2746. doi: 10.1126/sciadv.abk2746. Epub 2022 May 20. Sci Adv. 2022. PMID: 35594351 Free PMC article.

2

The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population.

Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P. Rodrigues P, et al. Among authors: tormo e. Breast Cancer Res Treat. 2012 Jun;133(2):769-78. doi: 10.1007/s10549-012-1980-1. Breast Cancer Res Treat. 2012. PMID: 22315135

3

Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.

Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P. Rodrigues P, et al. Among authors: tormo e. Mol Cell Biochem. 2013 Jul;379(1-2):181-90. doi: 10.1007/s11010-013-1640-8. Epub 2013 Apr 6. Mol Cell Biochem. 2013. PMID: 23716179

4

MicroRNA profile in very young women with breast cancer.

Peña-Chilet M, Martínez MT, Pérez-Fidalgo JA, Peiró-Chova L, Oltra SS, Tormo E, Alonso-Yuste E, Martinez-Delgado B, Eroles P, Climent J, Burgués O, Ferrer-Lozano J, Bosch A, Lluch A, Ribas G. Peña-Chilet M, et al. Among authors: tormo e. BMC Cancer. 2014 Jul 21;14:529. doi: 10.1186/1471-2407-14-529. BMC Cancer. 2014. PMID: 25047087 Free PMC article.

5

MicroRNAs in Breast Cancer: One More Turn in Regulation.

Eroles P, Tormo E, Pineda B, Espin E, Lluch A. Eroles P, et al. Among authors: tormo e. Curr Drug Targets. 2016;17(9):1083-100. doi: 10.2174/1389450116666150213114103. Curr Drug Targets. 2016. PMID: 25694121 Review.

6

MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.

Tormo E, Pineda B, Serna E, Guijarro A, Ribas G, Fores J, Chirivella E, Climent J, Lluch A, Eroles P. Tormo E, et al. J Cell Biochem. 2015 Sep;116(9):2061-73. doi: 10.1002/jcb.25162. J Cell Biochem. 2015. PMID: 25802200

7

BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia.

Guillem V, Amat P, Collado M, Cervantes F, Alvarez-Larrán A, Martínez J, Tormo E, Eroles P, Solano C, Hernández-Boluda JC. Guillem V, et al. Among authors: tormo e. Leuk Res. 2015 Aug 28:S0145-2126(15)30367-2. doi: 10.1016/j.leukres.2015.08.014. Online ahead of print. Leuk Res. 2015. PMID: 26344465

8

The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer.

Cabello P, Pineda B, Tormo E, Lluch A, Eroles P. Cabello P, et al. Among authors: tormo e. Int J Mol Sci. 2016 Aug 10;17(8):1298. doi: 10.3390/ijms17081298. Int J Mol Sci. 2016. PMID: 27517917 Free PMC article.

9

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.

Tormo E, Adam-Artigues A, Ballester S, Pineda B, Zazo S, González-Alonso P, Albanell J, Rovira A, Rojo F, Lluch A, Eroles P. Tormo E, et al. Sci Rep. 2017 Jan 25;7:41309. doi: 10.1038/srep41309. Sci Rep. 2017. PMID: 28120942 Free PMC article.

10

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors.

Tormo E, Ballester S, Adam-Artigues A, Burgués O, Alonso E, Bermejo B, Menéndez S, Zazo S, Madoz-Gúrpide J, Rovira A, Albanell J, Rojo F, Lluch A, Eroles P. Tormo E, et al. Sci Rep. 2019 Mar 29;9(1):5316. doi: 10.1038/s41598-019-41472-y. Sci Rep. 2019. PMID: 30926829 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18 results

Search Page